Abstract

Typhoid has been reported to be a common and significant cause of morbidity in pre-school and school-age children in the endemic countries like India. The incidence of typhoid has been reported to be as high as 27.3 per 1000 person-years in children less than 5 years of age. Serious complications occur in about 10% of cases requiring hospitalization. The mean cost of treatment per episode of blood culture-confirmed typhoid fever has been calculated as INR 3,597 (1996 prices) in an outdoor setting, whereas in case of hospitalization, the cost of illness increases by several folds (INR 18,131). Vi polysaccharide vaccine is safe, efficacious and affordable for use as a cost-effective public health tool to protect children from typhoid and related complications, when given at 2 and 5 years of age as a part of National Immunization Schedule.

Details

Title
Typhoid vaccine: A case for inclusion in national program
Author
Sharma, Pragya 1 ; Taneja, Davendra 2 

 Assistant Professor, Department of Community Medicine, Maulana Azad Medical College, New Delhi, India, and Convener of Immunization Subcommittee, Indian Public Health Association 
 Director Professor, Department of Community Medicine, Maulana Azad Medical College, New Delhi, India, and Convener of Immunization Subcommittee, Indian Public Health Association 
Pages
267-271
Publication year
2011
Publication date
Oct 2011
Publisher
Medknow Publications & Media Pvt. Ltd.
ISSN
0019557X
e-ISSN
22297693
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2210989880
Copyright
© 2011. This work is published under https://creativecommons.org/licenses/by-nc-sa/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.